Deciphering the Prognostic and Therapeutic Significance of Cell Cycle Regulator CENPF: A Potential Biomarker of Prognosis and Immune Microenvironment for Patients with Liposarcoma.
Jiahao ChenYingying LianBinbin ZhaoJiayang HanXinyu LiJialin WuMengwen HouMan YueKaifeng ZhangGuangchao LiuMengjie TuWeimin RuanShaoping JiYang AnPublished in: International journal of molecular sciences (2023)
Liposarcoma (LPS) is one of the most common subtypes of sarcoma with a high recurrence rate. CENPF is a regulator of cell cycle, differential expression of which has been shown to be related with various cancers. However, the prognostic value of CENPF in LPS has not been deciphered yet. Using data from TCGA and GEO datasets, the expression difference of CENPF and its effects on the prognosis or immune infiltration of LPS patients were analyzed. As results show, CENPF was significantly upregulated in LPS compared to normal tissues. Survival curves illustrated that high CENPF expression was significantly associated with adverse prognosis. Univariate and multivariate analysis suggested that CENPF expression could be an independent risk factor for LPS. CENPF was closely related to chromosome segregation, microtubule binding and cell cycle. Immune infiltration analysis elucidated a negative correlation between CENPF expression and immune score. In conclusion, CENPF not only could be considered as a potential prognostic biomarker but also a potential malignant indicator of immune infiltration-related survival for LPS. The elevated expression of CENPF reveals an unfavorable prognostic outcome and worse immune score. Thus, therapeutically targeting CENPF combined with immunotherapy might be an attractive strategy for the treatment of LPS.
Keyphrases
- cell cycle
- poor prognosis
- inflammatory response
- cell proliferation
- anti inflammatory
- end stage renal disease
- stem cells
- chronic kidney disease
- transcription factor
- long non coding rna
- emergency department
- prognostic factors
- gene expression
- dna methylation
- ejection fraction
- data analysis
- drug delivery
- cancer therapy
- dna binding
- big data